Frequency and prognostic significance of hypercalcemia in patients with multiple myeloma
| Autor: | Kanar J Karim, Abid M Hassan, Hisham A Getta, Najmaddin S. H. Khoshnaw, Sana D Jalal, Akram M Mohammed, Kawa M Hasan, Dana A Abdullah, Ameer I A. Badi, Ahmed K Yassin, Banaz M Safar, Basil K Abdulla, Rawand P Shamoon, Truska A Amin, Zeki A Mohamed, Ali I Mohammed, Diveen J Hussein, Nawsherwan S Mohammed, Rezhin N Rajab, Firiad Hiwaizi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Medical Journal of Babylon, Vol 17, Iss 4, Pp 327-331 (2020) |
| Druh dokumentu: | article |
| ISSN: | 1812-156X 2312-6760 |
| DOI: | 10.4103/MJBL.MJBL_54_20 |
| Popis: | Background: Multiple myeloma (MM) is defined as a clonal B-cell malignancy of the bone marrow. Hypercalcemia is associated with cancers in general and in MM specifically becomes more obvious with frequent adverse outcomes. Objectives: The objective is to determine the frequency of hypercalcemia in MM patients and survival rate after 3 years of diagnosis with the assessment of relationship between MM prognosis and hypercalcemia. Materials and Methods: Retrospective data were reviewed from the Hematology and Cancer Centers of Kurdistan Region of Iraq (KRI, Erbil, Sulaymaniyah, and Duhok) from January 2012 to December 2017 on a sample of 130 patients with MM. The diagnosis of MM and hypercalcemia was done according to the International Myeloma Working Group definition of MM and serum calcium of ≥11 mg/dl. Results: The prevalence of hypercalcemia among MM patients after calcium correction was 17.7%. Serum creatinine level is significantly higher among MM patients with hypercalcemia. There was a significant association between high death rates and MM patients with hypercalcemia. The mean survival of MM patients was 4.5 years and 72% of the MM patients had 3-year survival, which decreased to |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|